A medication is being researched in mice that affects myelin regeneration in animals with multiple sclerosis.
A new treatment for people suffering from multiple sclerosis (MS) may be on its way, scientists claim, after tests on mice showed promising results. The drug fluorosamine – not yet approved for use in humans – has the potential to boost myelin regeneration, a key step in curing patients.
The research, published in Nature Communications, is based on the fact MS is caused by damage to myelin, the isolating sheath composed of lipids and proteins wrapped around nerve fibres in the brain and spinal cord.
In patients with MS, the immune system attacks the myelin sheath. After that, myelin regeneration is often troublesome because specific molecular signals – called the CSPGs – block the production of cells known as OPCs, which are responsible for myelin production.
Using an MS mouse model, the researchers discovered evidence that fluorosamine can help tackle this specific problem, triggering the growth of OPCs in the presence of CSPGs.
|Read Full Article: Multiple sclerosis: Drug boosts myelin regeneration in mice raising hope of future treatments for MS|